Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Actinium Pharmaceuticals (NYSE: ATNM) has unveiled promising preclinical data for its Antibody Radiation Conjugate (ARC) Actimab-A, in combination with menin inhibitors, at the 2024 European Hematology Association Congress. The study showed enhanced AML cell death and a synergistic anti-tumor effect in AML models with KMT2A rearrangements and NMP1 mutations, affecting around 40% of AML patients. These results suggest potential as a combination therapy across various AML treatment stages. This news, alongside the broader USD 2.1 billion AML treatment market expected to grow at a CAGR of 10.7% by 2024, highlights Actinium's growing footprint in the AML therapeutic landscape.
- Actimab-A showed potent AML cell killing activity.
- Combination with menin inhibitors enhanced AML cell death.
- Synergistic anti-tumor effect observed in preclinical models.
- Huge market potential, with AML treatment market valued at USD 2.1 billion in 2023 and estimated to grow at a CAGR of 10.7%.
- Broad applicability of Actimab-A with other therapies, including chemotherapy and immunotherapies.
- Positive initial data encouraging further clinical studies.
- The data presented is preclinical, requiring further validation in clinical trials.
- Potential risks associated with drug development, including failure in future trials.
- No immediate impact on revenue as clinical development continues.
- Uncertainty on how quickly the combination therapy can be brought to market.
Insights
Actinium Pharmaceuticals' combination of Actimab-A with menin inhibitors in treating acute myeloid leukemia (AML) shows notable promise. The preclinical data suggests significant potentiation of anti-tumor effects compared to monotherapies. The combination therapy, particularly potent in difficult-to-treat KMT2A AML, may represent a meaningful advancement in therapy, potentially addressing unmet needs in both frontline and relapsed/refractory settings.
Overall, Actimab-A's broad applicability, targeting CD33, a marker expressed in nearly all AML patients, combined with the efficacy in preclinical models, supports its potential as a backbone therapy across the AML treatment continuum. However, these findings are preliminary and further clinical studies are essential to validate these benefits in a real-world setting.
This development is significant for stakeholders, presenting a potential shift in AML treatment paradigms, albeit with the usual clinical trial risks associated.
The combination of Actimab-A and menin inhibitors presents a synergistic approach to AML treatment. Actimab-A's use of targeted radiotherapy, conjugated with the alpha-particle payload Actinium-225, leverages CD33's universal expression in AML. This could provide a robust treatment option, particularly for patients with KMT2A rearrangements and NMP1 mutations, which are typically challenging to manage.
The rapid induction of cell death within 72 hours and enhanced anti-tumor effects when used in combination therapy are promising, suggesting this approach may be particularly beneficial for high-risk, relapsed and refractory patients. While these results are from preclinical studies, the implications for clinical use are substantial, potentially improving survival outcomes and offering a new standard of care for these patient subsets.
From a financial perspective, Actinium Pharmaceuticals' progress with Actimab-A in combination with menin inhibitors could significantly enhance its market position. The AML market, valued at
For investors, Actinium's diversified pipeline, including Iomab-B for older AML patients, further strengthens its portfolio. The potential for Actimab-A to serve as a backbone therapy across various AML treatment stages enhances its commercial viability. However, the inherent risks of clinical development, regulatory approval and market competition must be considered. If upcoming clinical trials reinforce these preclinical results, Actinium could see significant long-term financial gains.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the companies developing innovative solutions, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies.
Read the full article on Investorideas
https://www.investorideas.com/News/2024/biotech/06170Biopharma-Stocks.asp
"Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. AML mostly affects cells that aren't fully developed, leaving these cells unable to carry out their normal functions. It can be a difficult disease to treat; researchers are studying new approaches to AML therapy in clinical trials," says the Leukemia Lymphoma Society.
There is a huge market opportunity for companies that offer solutions for AML. The Acute Myeloid Leukemia Market was valued at USD 2.1 billion in 2023 and is estimated to grow at a CAGR of
With breaking news on AML treatment, Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) just announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models was presented at the 2024 European Hematology Association (EHA) Congress held June 13 - 16, 2024, in Madrid, Spain. Actinium studied Actimab-A in combination with the leading menin inhibitors, revumenib (Syndax Pharmaceuticals, Inc.) and ziftomenib (Kura Oncology, Inc.), which are being developed for patients with KMT2A rearrangements and NMP1 mutations, which are present in approximately
Actimab-A + Menin inhibitor combination results include:
Actimab-A as a single agent showed potent AML cell killing activity in KMT2A harboring cells in both MV-4-11 and MOLM-13 cell lines in vitro compared to the non-radio conjugated CD33 antibody lintuzumab (p<0.0001)
Actimab-A enhanced AML cell death when combined with both revumenib and ziftomenib at all dose levels in difficult to treat KMT2A AML
The combination of Actimab-A with leading menin inhibitors triggered an acute increase in AML necrosis and cell death relative to single agent therapy within 72 hours of dosing
Anti-tumor effect was significantly potentiated and prolonged when combining Actimab-A with a leading menin inhibitor compared to monotherapies in xenograft leukemia models in vivo (p<0.0024 Actimab-A + menin) as shown in the exhibit below
The Actimab-A + Menin Inhibitor combination presentation can be accessed on the investor relations page of Actinium's website here.
More from the news: Actimab-A targets CD33, a marker expressed ubiquitously in patients with AML, and is conjugated with the alpha-partible payload Actinium-225. The broad expression of CD33 and the differentiated mutation agnostic cell-killing mechanism of targeted radiotherapy make Actimab-A broadly applicable for combinations with chemotherapy, targeted agents including venetoclax, FLT3 and menin inhibitors, immunotherapies and cellular therapies supporting its potential backbone therapy profile across the AML patient treatment journey.
Sandesh Seth, Actinium's Chairman and CEO said, "Combining with menin inhibitors is an exciting expansion of the already broad potential of Actimab-A in AML. Across single agent and combination studies, Actimab-A has produced high rates of response, MRD negativity and improved survival in high-risk, relapsed and refractory patients including those with a TP53 mutation and venetoclax failures. The broad expression of CD33 in AML coupled with the potency of Actinium-225 make Actimab-A an ideal agent for treating radiation sensitive AML. We are encouraged by this highly promising initial data and the synergistic potential of Actimab-A with menin inhibitors, which has broad potential across the AML treatment continuum including frontline, maintenance and relapsed/refractory settings. We are eager to continue to study this combination and generate additional data that could support advancing into clinical studies of Actimab-A with menin inhibitors."
More from the news: Menin inhibitors are a class of drug candidates being developed for patients with AML that have a rearrangement of the KMT2A gene, previously known as the mixed-lineage leukemia (MLL) or mutation of the NPM1 gene. There are multiple menin inhibitors in development for these patients with revumenib (Syndax Pharmaceuticals, Inc.) being most advanced having a PDUFA data of September 2024 and ziftomenib (Kura Oncology, Inc.) enrolling patients in a registration Phase 2 trial. Multiple menin inhibitors are being studied in Phase 1 clinical trials by companies including Johnson & Johnson, Sumitomo Pharma Co., Ltd., Hutchmed, Biomea Fusion, Inc. and BioNova Pharmaceuticals Pvt Ltd.
Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced it has presented interim results from the Company's Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) in a poster presentation at 2024 European Hematology Association (EHA) Congress, on June 14, 2024 in Madrid, Spain.
More from the News: Jorge Cortes, M.D., Director of the Georgia Cancer Center, presented data showing prexigebersen continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
"It was a pleasure to present these compelling data to an audience of European oncologists who treat AML patients and understand the continued great need for new therapeutic options," said Peter Nielsen, Chief Executive Officer of Bio-Path. "Given that our study is being conducted in the U.S., this encore presentation is an important step towards educating global oncology leaders on the benefits of prexigebersen and its potential to be another tool in their fight against AML."
Also looking for answers for AML patients, Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a potential new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, recently announced updated interim data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. These data are to be featured in a poster presentation on June 14, 2024 at 18:00 CEST, during the European Hematology Association (EHA) 2024 Congress.
"We are pleased to present additional data from our Phase 1B dose expansion clinical trial, which further supports our differentiated mechanism of action and underscores SL-172154's emergence as the leading CD47 inhibitor in hematologic malignancies," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "This update shows that the rate of complete remission has improved since our last data release in December, with additional patients in both cohorts who continue to improve on therapy. As a result of these encouraging data, and our expectation of rapid enrollment and progress in our ongoing randomized, controlled cohort in HR-MDS, we are focusing our efforts on our opportunity in HR-MDS and TP53m AML. These are indications with high unmet need, limited competition, and potential for accelerated paths to approval."
More from the news: Dr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck added, "We are encouraged by the maturing data that continues to underscore the therapeutic potential, and manageable safety profile, of SL-172154 for patients with previously untreated HR-MDS and TP53m AML. Accumulating clinical evidence now shows the pharmacodynamic contribution of CD40 activation in the peripheral blood, and an emerging correlation between clinical remission and CD40 mediated induction of certain cytokines. The TP53m AML and HR-MDS patients we have treated represent a high-risk group with short duration of complete remission and overall survival when treated with azacitidine alone. Median overall survival and duration of remission have not yet been achieved, and we look forward to sharing additional durability data later this year. Enrollment is now underway for our randomized, controlled expansion cohort in frontline HR-MDS patients, and we expect to engage in regulatory discussions later this year regarding the registrational strategy for SL-172154."
Moleculin Biotech, Inc.,, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, last week reported additional efficacy findings from the Company's ongoing Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of subjects with acute myeloid leukemia (AML). The preliminary data was presented at the European Hematology Association (EHA) 2024 Hybrid Congress. The Company also hosted a data presentation to leading AML experts as part of a KOL meeting held in conjunction with EHA 2024 Congress.
More from the news: To date, a total of 22 subjects have been enrolled (the Intent-to-Treat population, ITT), 20 (Lines 1st-7th) of whom have completed efficacy evaluations with 9 subjects (
Of the 10 ITT subjects for whom AnnAraC was administered in the 2nd line setting, 5 achieved a CR (
Continued: Additionally,
The American Cancer Society's estimates for leukemia in the United States for 2024 are: "About 62,770 new cases of leukemia (all kinds) and 23,670 deaths from leukemia (all kinds), .about 20,800 new cases of acute myeloid leukemia (AML);most will be in adults. About 11,220 deaths from AML; almost all will be in adults."
In addition to Actinium's (NYSE American: ATNM) ARC Actimab-A, Iomab-B, their lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT.
Actinium's ambitions expand beyond AML, with the company saying, "We are continuing to expand our drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors. Our intellectual property portfolio includes more than 220 patents and patent applications worldwide."
Research biotech and medical device/ tech stocks at Investorideas.com
https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.
Disclaimer/Disclosure: This news article featuring ATNM is a paid for news release creation and dissemination on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on X @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213222
FAQ
What is the recent development announced by Actinium Pharmaceuticals (ATNM) for AML treatment?
How did Actimab-A perform in preclinical studies?
What market potential exists for AML treatments?
What makes Actimab-A a promising treatment for AML?
What are the risks associated with Actimab-A's development for AML?
